**Supplementary Table S3. Baseline characteristics of participants stratified by *SAMM50-rs738491*, *PARVB-rs5764455* and *PNPLA3-rs738409* genotypes.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | ***SAMM50-rs738491*** | | | | ***PARVB-rs5764455*** | | | | ***PNPLA3-rs738409*** | | | |
|  | **CC** | **CT** | **TT** | ***p*** | **GG** | **GA** | **AA** | ***p*** | **CC** | **CG** | **GG** | ***p*** |
| *n* (%) | 86 (20.72) | 196 (47.23) | 133 (32.05) |  | 121 (29.16) | 207 (49.88) | 87 (20.96) |  | 126 (30.36) | 190 (45.78) | 99 (23.86) |  |
| Female sex (%) | 20 (23.26) | 38 (19.39) | 42 (31.58) | 0.039 | 31 (25.62) | 39 (18.84) | 30 (34.48) | 0.015 | 31 (24.60) | 39 (20.53) | 30 (30.30) | 0.180 |
| Age, years | 43 (35-51) | 42 (31-50) | 41 (32-49) | 0.973 | 43 (36-51) | 41 (31-49) | 42 (31-52) | 0.504 | 43 (35-51) | 42 (30-50) | 42 (33-48) | 0.299 |
| BMI, kg/m2 | 26.36 (23.29-28.60) | 26.64 (24.58-28.74) | 26.95 (24.63-28.80) | 0.140 | 26.37 (23.46-28.62) | 26.84 (24.49-28.74) | 26.53 (24.65-28.73) | 0.324 | 26.59 (23.49-28.92) | 26.81 (24.52-28.79) | 26.63 (24.62-28.67) | 0.395 |
| Hypertension |  |  |  | 0.432 |  |  |  | 0.062 |  |  |  | 0.477 |
| Yes | 26 | 75 | 48 |  | 33 | 81 | 35 |  | 40 | 73 | 36 |  |
| No | 60 | 121 | 85 |  | 88 | 126 | 52 |  | 86 | 117 | 63 |  |
| T2DM |  |  |  | 0.621 |  |  |  | 0.554 |  |  |  | 0.183 |
| Yes | 21 | 46 | 26 |  | 31 | 45 | 17 |  | 35 | 36 | 22 |  |
| No | 65 | 150 | 107 |  | 90 | 162 | 70 |  | 91 | 154 | 77 |  |
| HOMA-IR | 3.34 (2.02-4.83) | 3.60 (2.44-6.19) | 3.16 (2.12-4.98) | 0.213 | 3.37 (2.17-4.84) | 3.60 (2.44-5.92) | 3.09 (2.04-5.12) | 0.655 | 3.49 (2.02-5.18) | 3.25 (2.41-5.35) | 3.43 (2.15-5.25) | 0.650 |
| ALT, U/L | 44 (25.8-77.3) | 51 (32.3-91.3) | 55 (36-99) | 0.693 | 45 (28-74.5) | 51 (32-102) | 60 (37-101) | 0.510 | 44 (27-72.3) | 53.5 (33-106) | 56 (36-91) | 0.325 |
| AST, U/L | 31 (24-52) | 34 (26-53) | 36 (26-60) | 0.501 | 31 (24-47.5) | 34 (25-55) | 38 (26-61) | 0.692 | 31 (24-47.3) | 34.5 (26-57.3) | 37 (26-59) | 0.500 |
| GGT, U/L | 51 (27-84.8) | 51.5 (35.3-84.3) | 52 (32-80.5) | 0.959 | 49 (29-79.5) | 54 (36-90) | 51 (31-77) | 0.783 | 48 (29-80.3) | 54.5 (34.8-86) | 51 (33-80) | 0.910 |
| TG, mmol/L | 1.89 (1.34-3.06) | 2.01 (1.33-2.86) | 1.82 (1.44-2.54) | 0.093 | 1.95 (1.33-3.01) | 1.98 (1.44-2.84) | 1.82 (1.33-2.50) | 0.100 | 1.96 (1.30-3.10) | 1.94 (1.39-2.87) | 1.87 (1.45-2.41) | 0.128 |
| TC, mmol/L | 4.90±1.09 | 4.95±1.13 | 5.20±1.12 | 0.080 | 4.97±1.17 | 4.97±1.07 | 5.22±1.15 | 0.167 | 4.90±1.17 | 5.05±1.09 | 5.13±1.12 | 0.274 |
| HDL-C, mmol/L | 0.93 (0.81-1.11) | 0.96 (0.86-1.13) | 1.01 (0.89-1.16) | 0.094 | 0.94 (0.83-1.11) | 0.98 (0.87-1.14) | 1.03 (0.89-1.15) | 0.338 | 0.95 (0.84-1.10) | 0.97 (0.87-1.14) | 1.02 (0.89-1.19) | 0.167 |
| LDL-C, mmol/L | 2.93±0.86 | 2.97±0.90 | 3.23±0.89 | 0.014 | 2.99±0.89 | 2.97±0.86 | 3.30±0.96 | 0.011 | 2.92±0.90 | 3.06±0.88 | 3.18±0.92 | 0.081 |
| UA, mmol/L | 359 (304-473) | 394 (338-466) | 380 (327-452) | 0.115 | 372 (307-465) | 400 (336-466) | 378 (334-456) | 0.188 | 371 (300-471) | 400 (343-466) | 377 (325-441) | 0.086 |
| Liver histology features |  |  |  |  |  |  |  |  |  |  |  |  |
| NAS ≥4 |  |  |  | 0.003 |  |  |  | 0.001 |  |  |  | 0.001 |
| Yes | 43 | 111 | 95 |  | 59 | 125 | 65 |  | 61 | 115 | 73 |  |
| No | 43 | 85 | 38 |  | 62 | 82 | 22 |  | 65 | 75 | 26 |  |
| Fibrosis stage |  |  |  | 0.900 |  |  |  | 0.559 |  |  |  | 0.932 |
| F≥2 | 20 | 41 | 28 |  | 30 | 41 | 18 |  | 27 | 42 | 20 |  |
| F<2 | 66 | 155 | 105 |  | 91 | 166 | 69 |  | 99 | 148 | 79 |  |

Sample size *n*=415. Data are expressed as number (percentage) for categorical variables, as mean±SD for normally distributed continuous variables and median (interquartile range) for skewed distributed continuous variables. Differences among the groups were determined using the one-way ANOVA for continuous variables, as well as the chi-squared test for categorical variables.